Cutting edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells

Adam P. Kohm, Jeffrey S. McMahon, Joseph R. Podojil, Wendy Smith Begolka, Mathew DeGutes, Deborah J. Kasprowicz, Steven F. Ziegler, Stephen D. Miller*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

260 Scopus citations

Abstract

CD4+CD25+ T regulatory (TR) cells are an important regulatory component of the adaptive immune system that limit autoreactive T cell responses in various models of autoimmunity. This knowledge was generated by previous studies from our lab and others using TR cell supplementation and depletion. Contrary to dogma, we report here that injection of anti-CD25 mAb results in the functional inactivation, not depletion, of TR cells, resulting in exacerbated autoimmune disease. Supporting this, mice receiving anti-CD25 mAb treatment display significantly lower numbers of CD4+CD25+ T cells but no change in the number of CD4+ FoxP3+ TR cells. In addition, anti-CD25 mAb treatment fails to both reduce the number of Thy1.1+ congenic CD4+CD25+ TR cells or alter levels of CD25 mRNA expression in treatment recipients. Taken together, these findings have far-reaching implications for the interpretation of all previous studies forming conclusions about CD4+CD25+ TR cell depletion in vivo.

Original languageEnglish (US)
Pages (from-to)3301-3305
Number of pages5
JournalJournal of Immunology
Volume176
Issue number6
DOIs
StatePublished - Mar 15 2006

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Cutting edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4<sup>+</sup>CD25<sup>+</sup> T regulatory cells'. Together they form a unique fingerprint.

Cite this